Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesExagen Inc

Exagen Inc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
7.69 USD -0.82 ( 9.64%)
Last update at 2026-11-05T18:00:00Z
VOLUME
255338
Market Cap
181.45M

Momentum Score

…

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.59
Low
8.48
High
52 Week Price Range
2.59
Low
12.23
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
8.51
Dividend Yield
-
Revenue TTM
71.12M
Revenue Per Share
3.01
Gross Profit TTM
41.70M
Debt / Equity
1.47
ROE
-113.82%
Net Debt
-6.51M
ROCE
-35.52%
Diluted EPS TTM
-0.83

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -19.90M -15.10M -23.66M -47.67M -26.68M
Net income -19.95M -15.12M -23.69M -47.39M -26.85M
Selling general administrative 46.62M 39.97M 45.93M 52.02M 44.54M
Selling and marketing expenses - 1.40M 1.50M - -
Gross profit 38.80M 33.11M 29.46M 21.35M 27.71M
Reconciled depreciation 2.12M 1.72M 2.18M 1.56M 0.95M
Ebit -15.58M -12.87M -21.32M -40.55M -24.07M
Ebitda -13.46M -11.14M -19.15M -39.72M -24.05M
Depreciation and amortization 2.12M 1.72M 2.17M 0.83M 0.02M
Non operating income net other - - - - 0.02M
Operating income -14.07M -13.64M -22.84M -40.55M -24.07M
Other operating expenses 80.64M 69.28M 75.39M 86.11M 72.37M
Interest expense 4.32M 2.23M 2.33M 2.45M 2.62M
Tax provision 0.05M 0.01M 0.03M -0.28M 0.17M
Interest income 0.29M 0.77M 1.52M 0.83M -
Net interest income -4.03M -1.47M -1.56M -1.62M -2.62M
Income tax expense 0.05M 0.01M 0.03M -0.28M 0.17M
Total revenue 66.58M 55.64M 52.55M 45.56M 48.30M
Total operating expenses 52.87M 46.75M 52.29M 61.89M 51.78M
Cost of revenue 27.78M 22.53M 23.09M 24.21M 20.59M
Total other income expense net -5.83M -1.47M -0.82M -7.12M -2.61M
Net income from continuing ops -19.95M -15.12M -32.47M -47.39M -26.85M
Net income applicable to common shares - - - -47.39M -26.85M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 58.02M 44.69M 56.94M 86.22M 123.44M
Other current assets 5.82M 0.86M 1.93M 4.14M 3.64M
Total liab 40.57M 35.15M 34.25M 43.76M 38.51M
Total stockholder equity 17.45M 9.54M 22.69M 42.46M 84.94M
Other current liab 6.33M 8.95M 7.04M 5.35M 6.24M
Common stock 0.02M 0.02M 0.02M 0.02M 0.02M
Capital stock 0.02M 0.02M 0.02M 0.02M 0.02M
Retained earnings -314.28M -294.33M -279.22M -255.53M -208.14M
Other liab - - - 0.02M 1.71M
Good will - - - 0.00M 5.51M
Other assets - - - 0.53M 0.43M
Cash 32.22M 22.04M 36.49M 62.39M 99.44M
Total current liabilities 14.16M 13.51M 11.90M 9.62M 9.32M
Current deferred revenue 0.68M - - - -
Net debt -6.51M 0.97M -12.77M -27.89M -71.96M
Short term debt 3.00M 0.42M 1.73M 1.23M 0.59M
Short long term debt 0.64M 0.42M 0.26M 0.19M -
Short long term debt total 25.71M 23.00M 23.72M 34.50M 27.48M
Other stockholder equity 331.71M 303.85M 301.89M 297.97M 293.06M
Property plant equipment - - - 13.08M 4.77M
Total current assets 48.89M 36.45M 47.84M 72.61M 112.73M
Net tangible assets - - - 42.46M 79.43M
Net receivables 10.86M 7.83M 6.55M 6.08M 9.65M
Long term debt 22.26M 19.82M 19.23M 28.78M 27.48M
Inventory - - 2.87M 1.79M 1.09M
Accounts payable 4.15M 4.14M 3.13M 3.05M 2.49M
Accumulated other comprehensive income - - 0.00M - -
Common stock total equity - - - - 0.02M
Retained earnings total equity - - - - -208.14M
Non currrent assets other 0.56M 0.55M 0.42M 0.53M 0.43M
Non current assets total 9.13M 8.23M 9.10M 13.61M 10.71M
Capital lease obligations 2.80M 2.76M 4.23M 6.23M 0.59M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.52M -1.13M -4.32M -2.42M
Change to liabilities - - - 0.90M 0.33M
Total cashflows from investing activities -0.63M -0.52M -0.80M -4.32M -2.42M
Net borrowings 2.88M -0.86M -10.94M -0.70M -0.53M
Total cash from financing activities 24.43M -0.66M -10.63M -0.49M 64.68M
Change to operating activities - - - -2.81M 1.34M
Net income -19.95M -15.12M -23.69M -47.39M -26.85M
Change in cash 10.18M -14.46M -25.90M -36.95M 41.99M
Begin period cash flow 22.24M 36.69M 62.59M 99.54M 57.55M
End period cash flow 32.42M 22.24M 36.69M 62.59M 99.54M
Total cash from operating activities -13.62M -13.28M -14.46M -32.14M -20.27M
Issuance of capital stock 22.02M 0.00M - 0.00M 69.14M
Depreciation 2.12M 1.72M 2.17M 1.56M 0.95M
Other cashflows from investing activities - - 0.02M - -0.05M
Dividends paid - - 9.94M - -0.39M
Change to account receivables -3.02M -1.28M -0.47M 3.58M -0.74M
Sale purchase of stock - 0.18M 0.28M 0.39M 0.39M
Other cashflows from financing activities - 0.20M 0.31M -0.24M -3.94M
Change to netincome - - - 11.86M 5.42M
Capital expenditures 0.64M 0.52M 0.83M 4.32M 2.37M
Change receivables - - - - -0.74M
Cash flows other operating - - - - 0.35M
Cash and cash equivalents changes - - - - 41.99M
Change in working capital -1.98M -3.08M 0.33M 1.67M -0.06M
Stock based compensation 2.16M 1.76M 3.62M 4.70M 4.73M
Other non cash items 4.03M 1.43M 3.12M 7.62M 0.82M
Free cash flow -14.27M -13.79M -15.29M -36.46M -22.64M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
XGN
Exagen Inc		 -0.82
9.64%		 7.69 - - 2.55 14.62 2.53 -0.16
TMO
Thermo Fisher Scientific Inc		 -20.88
2.96%		 685.28 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -6.47
2.75%		 228.46 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 26.96 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -
-%		 25.11 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

Exagen Inc

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

1261 Liberty Way, Vista, CA, United States, 92081

760 560 1501

https://www.exagen.com

216

Name Title Year Born
Mr. Kamal Adawi M.S., MBA CFO & Corp. Sec. 1979
Mr. John Aballi CEO, Pres & Director 1985
Mr. Mark Hazeltine Chief Bus. Officer & COO 1974
Dr. Ming-Chou Lee Ph.D. Chief Technology Officer NA
Ryan Douglas Investors Relations Officer NA
Mr. John Wegener Sr. VP of Sales and Marketing 1969
Dr. Andrew L. Concoff FACR, M.D. Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board NA
Dr. Tina S. Nova Ph.D. Executive Chairman of the Board of Directors 1954
Mr. John Aballi CEO, President & Director 1985
Mr. Kamal Adawi M.S., MBA CFO & Corporate Secretary 1979

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…